CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,213 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02433366
NCT02433366N/ACompleted

Post-authorisation Study to Evaluate the Effectiveness of the Risk Minimisation Activities in the Treatment of SPAF

Boehringer Ingelheim·observational·Posted May 5, 2015·Updated Sep 19, 2016

In Brief

An observational study for Atrial Fibrillation. Completed, enrolled 1,213 participants across 161 sites in 8 countries.

Detailed Summary

The key focus of this survey will be to collect data on physicians awareness of the content of the Pradaxa® Prescriber Guide and the extent to which risk awareness is communicated to patients. The data collected with atrial fibrillation patients will show if and how well this information is received and understood.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesBulgaria, Czechia, Denmark, France, Germany, Slovakia, Spain, United Kingdom
Collaborators--

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedMay 5, 2015
Enrollment StartJan 1, 2015
Primary CompletionAug 1, 2015
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 11.2 years ago